Drug intelligence / Profile preview

VIP-ASON

Development stage: Preclinical
Lead developer: Sichuan University
Modality: MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravenous, Subcutaneous, Inhalation

Overview

**VIP-ASON** is an experimental, non-radioiodinated tumor-targeted antisense construct consisting of a 15-mer phosphorothioate antisense oligonucleotide complementary to the translation-start region of **MYC mRNA**, delivered using a vasoactive intestinal peptide-polylysine carrier. The VIP carrier was intended to promote uptake into VIP receptor-positive tumor cells, while the antisense component was designed to suppress MYC expression. It was evaluated preclinically in athymic mice bearing HT29 human colon adenocarcinoma xenografts; unlike the corresponding radioiodinated VIP-131I-ASON construct, VIP-ASON did not show a statistically significant antitumor effect versus saline at the tested dose. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/15578065/))

Other names: VIP-ASON

Targets

MYC (MYC proto-oncogene protein)VPAC (VIP receptor family)

Beyond the preview

Go deeper on VIP-ASON.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VIP-ASON.

Explore the full profile